Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll
Financial Performance Overview for Q1 2026
Revenue Impacted by Currency Fluctuations and Divestitures
May 5 (Reuters) - Fresenius Medical Care said on Tuesday its revenue fell 6% in the first quarter of 2026, weighed down by significant currency effects, mainly from the weak U.S. dollar, and recent divestitures.
Quarterly Revenue and Market Expectations
The dialysis provider's revenue was 4.61 billion euros ($5.39 billion) in the quarter, broadly in line with consensus expectations of 4.59 billion euros, according to a poll by Vara Research.
Operating Income and Net Income Declines
The company said its transformation programme had caused one-time costs which drove a 14% decline in reported operating income and a 22% drop in reported net income.
Strategic Overhaul and Future Outlook
Transformation Programme Under CEO Helen Giza
The strategic overhaul FMC is undergoing under CEO Helen Giza is focused on improving profitability in its core kidney care business after being spun off from former parent Fresenius.
Financial Year 2026 Outlook
The company confirmed its outlook for the 2026 financial year.
Currency Exchange Rate Information
($1 = 0.8559 euros)
Reporting and Editorial Credits
(Reporting by Patricia Weiss, writing by Bernadette Hogg, editing by Milla Nissi-Prussak)
